Abcellera Biologics is trading 10.8% down at $10.95 amid a sharp risk-off session and broader market weakness. - No company-specific announcement explaining the November 5 decline was found; investor relations lists October 22 as its latest release, with Q3 results due November 9. - Reports link market weakness to continuing AI-stock losses and concerns about potential data-center restrictions after the U.S. midterm elections. - Major indexes and biotech also posted steep declines, supporting a broader-market explanation.